Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
暂无分享,去创建一个
E. Braunwald | D. Morrow | E. Velazquez | A. DeVore | A. Ambrosy | K. Mccague | C. Duffy | Xiangyi Meng | R. Rocha | Ricardo A. Rocha | Carol I. Duffy
[1] Akshay S. Desai,et al. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. , 2019, Circulation.
[2] E. Braunwald,et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.
[3] E. Braunwald,et al. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt‐pRo‐bnp in patients stabilized from an acute Heart Failure episode (PIONEER‐HF) trial , 2018, American heart journal.
[4] Akshay S. Desai,et al. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impa , 2018, Circulation. Heart failure.
[5] S. Solomon,et al. The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions , 2018, European journal of heart failure.
[6] G. Fonarow,et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. , 2018, Journal of the American College of Cardiology.
[7] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.
[8] C. O'connor,et al. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. , 2017, Journal of the American College of Cardiology.
[9] S. Solomon,et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF , 2017, European heart journal.
[10] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[11] S. Solomon,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.
[12] G. Filippatos,et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial , 2012, Heart Failure Reviews.